| Literature DB >> 30026841 |
Li Chen1, Ying-Lin Peng1, Shi-Yong Gu2, Hui Shen3, Dan-Dan Zhang1, Wen-Zhao Sun1, Jian-Hua Wu1, Xiao-Wu Deng1.
Abstract
Background: In practice, the dose perturbation effect of head and neck immobilization devices is often overlooked in intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC). Purpose of this study is to verify and analyze the dosimetric effect of head and neck immobilization devices on NPC multi-field IMRT.Entities:
Keywords: Dose attenuation; Head and neck immobilization device; Intensity modulated radiation therapy; Nasopharyngeal carcinoma; Skin dose
Year: 2018 PMID: 30026841 PMCID: PMC6036882 DOI: 10.7150/jca.24887
Source DB: PubMed Journal: J Cancer ISSN: 1837-9664 Impact factor: 4.207
Figure 1A: The head and neck immobilization device used for nasopharyngeal carcinoma radiation treatment. The white piece is the head, neck and shoulder fixation mask of thermoplastic. The blue piece is the head and neck rest of vacuumed styrofoam bag, and the black piece is the carbon fiber floor of the whole device; B: The anthropomorphic phantom used for the film dosimetry. The phantom is horizontally transected into 2.5 cm thick slices. Each slice has holes which are plugged with bone and soft tissue equivalent materials to mimick the head and neck anatomy of actual patients.
Planning target volumes dosimetric parameters () of the two kinds of plans studied for 10 cases of nasopharyngeal carcinoma.
| Targets | Parameters | Plan+ | Plan- | Diff (%) | |
|---|---|---|---|---|---|
| PTVnx | CR(%) | 96.07 ± 1.43 | 98.32 ± 0.89 | -2.35 ± 1.21 | < 0.01 |
| Dmean(Gy) | 72.37 ± 1.71 | 73.04 ± 1.55 | -0.93 ± 0.32 | < 0.01 | |
| HI | 0.07 ± 0.02 | 0.07 ± 0.02 | 0 | NA | |
| CI | 0.76 ± 0.09 | 0.68 ± 0.15 | 11.14 ± 13.55 | 0.01 | |
| PTVnd | CR(%) | 89.90 ± 7.10 | 98.27 ± 1.27 | -9.92 ± 8.62 | 0.01 |
| Dmean(Gy) | 66.20 ± 1.14 | 67.47 ± 1.09 | -1.92 ± 0.38 | < 0.01 | |
| HI | 0.07 ± 0.01 | 0.07 ± 0.01 | 2.92 ± 6.22 | 0.17 | |
| CI | 0.15 ± 0.08 | 0.15 ± 0.07 | -1.93 ± 15.73 | 1.00 | |
| PTV1 | CR(%) | 97.39 ± 0.94 | 98.85 ± 0.54 | -1.51 ± 0.69 | < 0.01 |
| Dmean(Gy) | 69.36 ± 2.73 | 70.09 ± 2.58 | -1.07 ± 0.40 | < 0.01 | |
| CI | 0.45 ± 0.10 | 0.43 ± 0.09 | 5.99 ± 2.91 | < 0.01 | |
| PTV2 | CR(%) | 94.21 ± 2.25 | 97.56 ± 0.90 | -3.60 ± 2.60 | < 0.01 |
| Dmean(Gy) | 60.39 ± 1.10 | 61.31 ± 1.09 | -1.52 ± 0.25 | 0.01 | |
| CI | 0.79 ± 0.02 | 0.76 ± 0.03 | 2.89 ± 3.54 | 0.03 |
Note: Diff (%) = ((Plan+) - (Plan-)) / (Plan+) × 100.
Abbreviations: Plan-, plan generated without immobilization device; Plan+, plan calculated from Plan- with immobilization device taken into accounted; PTV, planning target volume; CR, coverage rate; HI, homogeneity index; CI, conformity index.
Dose results of OARs between two kinds of plans in 10 cases of nasopharyngeal carcinoma ().
| OARs | Parameters | Plan+ | Plan- | Diff (%) | |
|---|---|---|---|---|---|
| PRV-BrainStem | Dmean(Gy) | 32.32 ± 3.17 | 32.59 ± 3.18 | -0.83 ± 1.05 | 0.03 |
| D2%(Gy) | 55.83 ± 3.42 | 56.08 ± 3.21 | -0.48 ± 1.82 | 0.47 | |
| PRV-Spinal | Dmean(Gy) | 33.66 ± 2.15 | 33.94 ± 2.18 | -0.86 ± 0.31 | < 0.01 |
| D2%(Gy) | 41.18 ± 0.71 | 41.53 ± 0.86 | -0.83 ± 1.31 | 0.08 | |
| Parotid | Dmean(Gy) | 38.67 ± 2.23 | 38.96 ± 2.30 | -0.80 ± 0.42 | < 0.01 |
| Tongue | Dmean(Gy) | 40.50 ± 4.63 | 41.19 ± 4.66 | -1.70 ± 0.54 | < 0.01 |
| Inner ear | Dmean(Gy) | 47.18 ± 3.73 | 47.59 ± 3.86 | -0.84 ± 0.83 | 0.01 |
| Middle ear | Dmean(Gy) | 39.12 ± 3.51 | 39.60 ± 3.64 | -1.22 ± 0.68 | < 0.01 |
| Larynx | Dmean(Gy) | 45.55 ± 3.38 | 45.95 ± 3.42 | -0.89 ± 0.45 | < 0.01 |
Note: Diff(%) = ((Plan+) - (Plan-)) / (Plan+) × 100.
Abbreviations: OAR, organ at risk; Plan-, plan generated without immobilization device; Plan+, plan calculated from Plan- with immobilization device taken into accounted; Dmean, mean dose. D2%, near-maximum dose.
Figure 3Three dimensional dose difference distribution map for a typical NPC case. Dose difference was calculated through subtracting Plan- from Plan+. (A: Cross-sectional plane, B: Sagittal plane, and C: Coronal plane).
Figure 4The measurements and TPS calculations point doses on posterior skin for ten NPC patients. The blue squares represent the doses EBT3 film measurement. The red diamonds are the Plan+ (dose calculating with immobilization devices) doses and the green triangles represent the Plan- (dose calculating without immobilization devices) doses.
Figure 2DVH results of Plan- and Plan+ for one typical patient with nasopharyngeal carcinoma. The solid lines represent the results of Plan- (calculated without immobilization device), and the dotted lines represent the results of Plan+ (calculated with the whole head and neck immobilization device included in the external body contour).